Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.
about
RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phaseRNA antisense abrogation of MAT1 induces G1 phase arrest and triggers apoptosis in aortic smooth muscle cellsCoordinate Notch3-hairy-related transcription factor pathway regulation in response to arterial injury. Mediator role of platelet-derived growth factor and ERKNonviral gene transfer to skeletal, smooth, and cardiac muscle in living animalsPhosphorothioate oligonucleotides induction into experimental choroidal neovascularization by HVJ-liposome system.Effective transfection of a cis element "decoy" of the nuclear factor-kappaB binding site into the experimental choroidal neovascularization.Potential for transcatheter application of antisense oligonucleotides for the treatment of vascular diseases.Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivoTherapeutic applications of transcription factor decoy oligonucleotidesIntimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury modelA gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme.Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cellular growthGenetic engineering of vein grafts resistant to atherosclerosisThe antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism.Local gene delivery to the vessel wall.Augmented cell cycle protein expression and kinase activity in atherosclerotic rabbit vessels.Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene.Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide.Biointerventional cardiology: the future interface of interventional cardiovascular medicine and bioengineering.Effects of local delivery of trapidil on neointima formation in a rabbit angioplasty model.Targeting the cell cycle machinery for the treatment of cardiovascular disease.Gene transfer of human hepatocyte growth factor into rat skin wounds mediated by liposomes coated with the sendai virus (hemagglutinating virus of Japan).In vivo identification of a negative regulatory element in the mouse renin gene using direct gene transferAdenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty.Vascular smooth muscle cell proliferation and regrowth after mechanical injury in vitro are Egr-1/NGFI-A-dependent.Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response.In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene.Cardiovascular gene delivery: The good road is awaitingInhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotidesGene therapy for the extension of vein graft patency: a review.Intratumoural administration of dendritic cells: hostile environment and help by gene therapy.The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.Potential role of CYLD (Cylindromatosis) as a deubiquitinating enzyme in vascular cells.Gene therapy of fibroproliferative vasculopathies: current ideas in molecular mechanisms and biomedical technology.Efficacy of cilostazol on uncontrolled coronary vasospastic angina: a pilot study.Delivery of large biopharmaceuticals from cardiovascular stents: a reviewGene therapy to prevent occlusion of venous bypass grafts.Coronary vein graft disease: pathogenesis and prevention.
P2860
Q24291853-C4215679-4A09-45FB-BC77-73CD621619DAQ28582065-43A2DA9F-7EB5-4875-9434-CAE68DB6B65BQ28583973-464613F1-242B-475D-85BE-72123C19AE0BQ30431522-79513B75-26A1-452D-A9D1-5284BE407765Q30716866-307278F0-CF80-4BA5-9E7A-5BE20FDBBBDDQ33185693-A43F0D93-434B-42D9-B430-5062CD6EAE99Q33568857-6C9654BE-6F80-4D03-BB98-9BBACEA5067EQ33650305-F59CADCA-D564-4950-81E0-628E897DAFA1Q34078075-9838F6A5-0F76-4C9D-B551-04981C1AF91BQ34138108-71009768-23C5-4251-B024-688166FE3160Q34150085-9656093B-BB24-4A51-9D73-ADCD9DB45585Q34159206-134CE6C0-1C01-41E5-A979-C7729DF2744FQ34182616-89F7A0DA-ED95-4D63-8F6F-4C9487C71F41Q34229552-7C195775-0537-45EF-A290-5D2ABE6FF124Q34339752-75DE6AF9-64D7-4126-840D-4101569404C7Q34407499-ED1267B7-F76C-443B-8EE6-6C6DD4991B71Q34418987-CEAD21E8-E2FA-4277-8CB8-F3BDFD0852AFQ34467100-00B898B0-2597-46AB-8E4B-60C5ADD613FBQ34693858-79FE64C2-6E64-4048-8A37-B1DAC8F7F290Q34893888-7397C00C-1A51-417B-BAB5-9CD2D2ACC963Q34981655-C253B55F-B406-4761-AF59-E70DD7C8EEB7Q35041906-088F6AEF-F832-4A62-A583-EFD2E33529ECQ35164884-7511024D-05CB-4626-BF4C-1DC9839BBEE9Q35747709-DE87221F-EEC6-442C-A166-128CFD1818F3Q35762528-46B4F74B-74FF-44F2-93F7-D2EFD0DD5C42Q35766125-F0D53E64-951C-45DE-8F13-C3A42A8933DEQ35787921-77FB9BDF-458E-425E-A40C-87C35FAB18B5Q35801091-90F17EFC-2627-49F9-8F82-0EFEDEBED353Q35871957-761592B9-815E-4157-B6A7-7343B8C2EBFFQ35915765-30D59334-892D-4F04-B1F6-6E9ABDD7BACDQ35935577-89B6A998-48EA-400F-8015-AE3B98705544Q36032833-59C6C291-9B94-4700-918D-D8DBAFFF26ABQ36040788-5622470F-917C-441B-BA2F-92FB11668418Q36405134-C0F757FC-140C-4DEE-90D0-FAF966BF779CQ36482246-5E4F6502-ED15-493F-8D7A-B75D5EB16833Q36690251-DC100497-54FC-4142-847C-1F6D100E6183Q36844494-3F9A4414-AFCF-4222-9B89-337DB8B9EA33Q36968009-EEBAB570-D575-4232-9B73-ABF3274FA96FQ37176430-C17A6897-DDB8-459C-A305-1985485C7CA8Q37215596-110791D2-4787-43B3-939F-BC4A852DD2F0
P2860
Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Single intraluminal delivery o ...... ion of neointimal hyperplasia.
@ast
Single intraluminal delivery o ...... ion of neointimal hyperplasia.
@en
type
label
Single intraluminal delivery o ...... ion of neointimal hyperplasia.
@ast
Single intraluminal delivery o ...... ion of neointimal hyperplasia.
@en
prefLabel
Single intraluminal delivery o ...... ion of neointimal hyperplasia.
@ast
Single intraluminal delivery o ...... ion of neointimal hyperplasia.
@en
P2093
P2860
P356
P1476
Single intraluminal delivery o ...... ion of neointimal hyperplasia.
@en
P2093
Ellison KE
Gibbons GH
Morishita R
Nakajima M
P2860
P304
P356
10.1073/PNAS.90.18.8474
P407
P577
1993-09-01T00:00:00Z